Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. - Wikidata - awgldk - TriplyDB

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

http://www.wikidata.org/entity/Q34300883

about

Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response Adoptive cell transfer as personalized immunotherapy for human cancer.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy.Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter.The immune system and cancer evasion strategies: therapeutic concepts.T-cell receptor-engineered T cells for cancer treatment: current status and future directions.Adoptive T Regulatory Cell Therapy for Tolerance Induction.Tumor-Associated Tertiary Lymphoid Structures: Gene-Expression Profiling and Their Bioengineering Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.Effector CD4 and CD8 T cells and their role in the tumor microenvironment.Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma.Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma.Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.IL-2 and Beyond in Cancer Immunotherapy.Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.Immunotherapies: Exploiting the Immune System for Cancer Treatment.Fusobacterium nucleatum and colorectal cancer: A review.Immunotherapy of melanoma Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies

P2860

Q26799073-9E1304A3-7480-4027-89A7-965E84CCB0FD Q34043643-4DD20E3A-9EFA-4BC5-A82D-E46351DE8552 Q34350259-7516B101-8549-41BE-AFC1-F3452F9DD8AB Q34849409-C623EA38-90D6-4D5D-83AD-B6FD0F12C4C7 Q35145392-CB8FCA92-7261-4DC0-A1DA-161B62D7E1A3 Q35981245-AA5F821D-F249-4049-BE33-88D5570F5535 Q36027584-D096779D-2C4C-4917-B9DD-61EE6E0F2A1D Q37065838-E94F43C8-3450-4E6B-A9CB-B32C88572AFC Q37320131-453ED02C-E362-4300-9BAE-DDC4F1B27210 Q37346107-21479AF5-F973-4631-9D55-F5CDC0E0D5D8 Q37590119-74674A70-DE6B-4C13-B00D-2CBE2DC50CF0 Q37619977-F1F44081-69CA-464B-BEA3-AE1751FDE9E9 Q38146713-7CB86944-7E33-4024-94C6-A2ECF41CD9E1 Q38149916-B995100E-5C61-4E81-B76A-677C2989EC3F Q38237522-0143A7F2-0F4B-491F-9AA5-7F1F23D1E47C Q38636573-553384CE-8D92-4638-A757-65F9B48A6760 Q38654324-3E62BDAE-9A0B-46A0-837A-66678A669070 Q38691172-06870243-B8FC-4F71-949F-7B0C018EFB0E Q38767662-2C4D9437-9407-48E4-A555-82D136500C5F Q40132561-62D7B4F2-0CEE-45C0-8F1A-C844F696322F Q40996042-34270014-D029-499D-BF0D-9A69156BD41C Q41620209-824D646A-EC24-49E6-A0B4-91AD9601B58D Q42952683-ED6FD09B-293F-43E1-9D50-D7D44F57E7E9 Q45121629-42CFF241-8977-45CB-9EF5-A40D4C82FE62 Q45892989-A51B95C2-C17E-4030-9811-A9344454A2F3 Q45893061-F303E202-D71D-41D3-AF3B-9C15176F0670 Q47100020-90458FEE-273C-4FC7-85A6-C2DC4F136FDF Q47134263-A6AE42D8-6368-4A08-ABA6-A2077B102C32 Q50004232-D682CB48-98EF-4D37-A7DE-BB661783524F Q52649470-FC821E17-77A3-482D-A468-A5F349815F17 Q54976815-1BAF9791-3CA2-4B3F-9EEC-42A9C816236E Q54977188-6AD32F64-5465-49FE-BC7A-F63AF70CB13F Q55362851-4B14EBA3-C62F-49CE-8D18-4A9C15E79213 Q55398457-4E439E6F-577D-4BBB-8CB7-1944847AD169 Q56897379-475E6147-A01F-4438-841D-739D017D6174 Q57172250-EC17CB77-DF27-481E-A5A9-4FDAA05BCABC

P2860

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

http://www.wikidata.org/entity/Q34300883

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@ast

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@en

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@nl

type

label

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@ast

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@en

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@nl

prefLabel

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@ast

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@en

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@nl

P1433

Q34300883-4016FFBC-C240-45E7-8CF3-81392E36BF8A

P1476

Q34300883-8A89037C-0417-455A-8E3A-8C24901B5144

P2093

Q34300883-1D858FCC-D85B-4495-9CC2-3E7F6EE4597C

Q34300883-5C6F2A61-79A0-4042-A2B8-12A841317A11

Q34300883-6B9B02A8-28C4-4734-9521-083F186C029B

Q34300883-83CC3B04-8BA2-4B13-AE26-DEF5F34BBB5C

Q34300883-86E2FDB3-FA73-4A55-A316-CA54C4D0673D

Q34300883-89FDE81B-31B1-4F26-85A2-B2674E987344

Q34300883-B29EEEBD-D99F-4C28-BF28-DA31BD6DA5D6

Q34300883-B9A32C26-F84A-4328-B6A0-21318411A11F

Q34300883-CAB00F15-751E-4770-9813-DAC5389BAFF6

Q34300883-CCA1ABC7-C00B-4535-96A3-53FEFC16877A

P2860

Q34300883-012B7C1D-14DE-459E-94ED-A8091F6DB7B5

Q34300883-2D8D7BF8-8011-4130-95FB-33ECC7F33116

Q34300883-422851DA-3C3B-40BA-811B-395FA1132463

Q34300883-46D9B4AF-19F1-4CCF-A977-E09D67F4E517

Q34300883-7F6E6290-9B85-4ED8-B836-613CF36E14E8

Q34300883-A72C2928-962B-4174-80B5-DF69558927DC

Q34300883-B68A2752-541B-453E-9577-80F3C7A507C6

Q34300883-BB8AA9FB-AE5F-4807-AD68-0BDEA75474CB

Q34300883-C3AF25E6-5366-4C33-BC29-5507CB10058E

Q34300883-D6C5DE21-A09A-4856-9DDF-4E167D711C82

P304

Q34300883-9D9D397B-8DD6-472B-AA0A-C844EB212425

P31

Q34300883-14F282C0-D797-47DD-9600-328EF5683ED7

P356

Q34300883-0C9F1553-7D03-4A39-BACF-CA05F8B82792

P433

Q34300883-9E489AEA-5004-4865-9B5E-5BCB3EE37916

P478

Q34300883-F01A7AEC-B261-413D-AF41-190CC719777B

P50

Q34300883-DBB61BB6-2014-4C26-8603-88F4A75CF21F

P577

Q34300883-48BC6C22-EDBC-46CA-8D99-0DD272BD3CFF

P698

Q34300883-EEC4B956-D5BB-41EA-BC75-9CF6C6544348

P921

Q34300883-1649C519-0EB8-430B-A76E-ED0F5BD96F52

P932

Q34300883-6B5CAC1D-BD9D-44ED-BABB-92E0AA1E2648

P356

CJI.0B013E31826E8F5F

P1433

Journal of Immunotherapy

P1476

Efficacy of adoptive cell tran ...... ction for metastatic melanoma.

@en

P2093

Amod A Sarnaik

http://www.w3.org/2001/XMLSchema#string

Erica Royster

http://www.w3.org/2001/XMLSchema#string

Geoffrey Gibney

http://www.w3.org/2001/XMLSchema#string

James J Mulé

http://www.w3.org/2001/XMLSchema#string

Jeffrey Weber

http://www.w3.org/2001/XMLSchema#string

Jonathan Zager

http://www.w3.org/2001/XMLSchema#string

Lisa Kuhn

http://www.w3.org/2001/XMLSchema#string

Ragini Kudchadkar

http://www.w3.org/2001/XMLSchema#string

Sabine Ellwanger

http://www.w3.org/2001/XMLSchema#string

Shari Pilon-Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

P304

615-620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/CJI.0B013E31826E8F5F

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

William Janssen

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22996367

http://www.w3.org/2001/XMLSchema#string

P921

P932

4467830

http://www.w3.org/2001/XMLSchema#string